{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:04:25Z","timestamp":1788260665611,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T00:00:00Z","timestamp":1487635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both groups at Month 3, but only at Months 6\u201312 in the HBeAg-negative group. Both groups exhibited a significant HBsAg decline with each successive year of treatment. An HBsAg decline of \u226575% from baseline, assessed at Months 3 and 12 of treatment in the HBeAg-positive and -negative patients, respectively, independently predicted a virological response and HBeAg seroconversion in the HBeAg-positive patients, an HBsAg level of &lt;100\u2009IU\/mL in the HBeAg-negative patients, and HBsAg loss in all the patients during treatment. HBsAg levels of &lt;3,000\u2009IU\/mL at baseline combined with an HBsAg decline of \u226575% from baseline provided a predictive algorithm for HBsAg loss (positive and negative predictive values: 70% and 100%, respectively) during 5 years of treatment. The proposed cutoffs for defining an HBsAg decline may assist clinicians in early assessments of treatment responses in genotype B-infected or C-infected CHB patients receiving entecavir therapy.<\/jats:p>","DOI":"10.1038\/srep42879","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T14:22:47Z","timestamp":1487686967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B"],"prefix":"10.1038","volume":"7","author":[{"given":"Cheng-Yuan","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsueh-Chou","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Heng","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hsiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,21]]},"reference":[{"key":"BFsrep42879_CR1","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJ Thompson","year":"2010","unstructured":"Thompson, A. J. et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51, 1933\u20131944, doi: 10.1002\/hep.23571 (2010).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/hep.21282","volume":"44","author":"K Wursthorn","year":"2006","unstructured":"Wursthorn, K. et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44, 675\u2013684, doi: 10.1002\/hep.21282 (2006).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","volume":"5","author":"HL Chan","year":"2007","unstructured":"Chan, H. L. et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5, 1462\u20131468, doi: 10.1016\/j.cgh.2007.09.005 (2007).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFsrep42879_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/hep.26436","volume":"58","author":"MJ Sonneveld","year":"2013","unstructured":"Sonneveld, M. J. et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58, 872\u2013880, doi: 10.1002\/hep.26436 (2013).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR5","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst, V. et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 52, 454\u2013461, doi: 10.1002\/hep.23722 (2010).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","volume":"54","author":"JG Reijnders","year":"2011","unstructured":"Reijnders, J. G. et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 54, 449\u2013454, doi: 10.1016\/j.jhep.2010.07.046 (2011).","journal-title":"J Hepatol"},{"key":"BFsrep42879_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn, K. et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 52, 1611\u20131620, doi: 10.1002\/hep.23905 (2010).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","volume":"61","author":"P Marcellin","year":"2014","unstructured":"Marcellin, P. et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol 61, 1228\u20131237, doi: 10.1016\/j.jhep.2014.07.019 (2014).","journal-title":"J Hepatol"},{"key":"BFsrep42879_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3851\/IMP1921","volume":"16","author":"HL Chan","year":"2011","unstructured":"Chan, H. L. et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 16, 1249\u20131257, doi: 10.3851\/IMP1921 (2011).","journal-title":"Antivir Ther"},{"key":"BFsrep42879_CR10","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen, C. H. et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 13, 1984\u20131992, e1981, doi: 10.1016\/j.cgh.2015.06.002 (2015).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"BFsrep42879_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/jir282","volume":"204","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk, R., Hansen, B. E., van Vuuren, A. J., Boucher, C. A. & Janssen, H. L. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 204, 415\u2013418, doi: 10.1093\/infdis\/jir282 (2011).","journal-title":"J Infect Dis"},{"key":"BFsrep42879_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.3851\/IMP2579","volume":"18","author":"EQ Chen","year":"2013","unstructured":"Chen, E. Q. et al. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment. Antivir Ther 18, 955\u2013965, doi: 10.3851\/IMP2579 (2013).","journal-title":"Antivir Ther"},{"key":"BFsrep42879_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jvh.12211","volume":"21","author":"T Hara","year":"2014","unstructured":"Hara, T. et al. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naive chronic hepatitis B patients. J Viral Hepat 21, 802\u2013808, doi: 10.1111\/jvh.12211 (2014).","journal-title":"J Viral Hepat"},{"key":"BFsrep42879_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jgh.12476","volume":"29","author":"WK Seto","year":"2014","unstructured":"Seto, W. K. et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol 29, 1028\u20131034, doi: 10.1111\/jgh.12476 (2014).","journal-title":"J Gastroenterol Hepatol"},{"key":"BFsrep42879_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3851\/IMP2559","volume":"18","author":"RG Gish","year":"2013","unstructured":"Gish, R. G. et al. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. Antivir Ther 18, 691\u2013698, doi: 10.3851\/IMP2559 (2013).","journal-title":"Antivir Ther"},{"key":"BFsrep42879_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jhep.2014.08.031","volume":"62","author":"F Zoulim","year":"2015","unstructured":"Zoulim, F. et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol 62, 56\u201363, doi: 10.1016\/j.jhep.2014.08.031 (2015).","journal-title":"J Hepatol"},{"key":"BFsrep42879_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/MCG.0b013e3181d52946","volume":"44","author":"YK Jung","year":"2010","unstructured":"Jung, Y. K. et al. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 44, 653\u2013657, doi: 10.1097\/MCG.0b013e3181d52946 (2010).","journal-title":"J Clin Gastroenterol"},{"key":"BFsrep42879_CR18","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/hep.24221","volume":"53","author":"JM Lee","year":"2011","unstructured":"Lee, J. M. et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 53, 1486\u20131493, doi: 10.1002\/hep.24221 (2011).","journal-title":"Hepatology"},{"key":"BFsrep42879_CR19","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1038\/ajg.2011.253","volume":"106","author":"J Fung","year":"2011","unstructured":"Fung, J. et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 106, 1766\u20131773, doi: 10.1038\/ajg.2011.253 (2011).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep42879_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2893.2012.01599.x","volume":"19","author":"JW Shin","year":"2012","unstructured":"Shin, J. W. et al. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat 19, 724\u2013731, doi: 10.1111\/j.1365-2893.2012.01599.x (2012).","journal-title":"J Viral Hepat"},{"key":"BFsrep42879_CR21","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3851\/IMP1866","volume":"16","author":"J Jaroszewicz","year":"2011","unstructured":"Jaroszewicz, J. et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside\/nucleotide analogues. Antivir Ther 16, 915\u2013924, doi: 10.3851\/IMP1866 (2011).","journal-title":"Antivir Ther"},{"key":"BFsrep42879_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw, Y. F. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6, 531\u2013561, doi: 10.1007\/s12072-012-9365-4 (2012).","journal-title":"Hepatol Int"},{"key":"BFsrep42879_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12072-010-9227-x","volume":"5","author":"CY Peng","year":"2011","unstructured":"Peng, C. Y. et al. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. Hepatol Int 5, 586\u2013596, doi: 10.1007\/s12072-010-9227-x (2011).","journal-title":"Hepatol Int"},{"key":"BFsrep42879_CR24","doi-asserted-by":"crossref","unstructured":"The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20, 15\u201320, doi: 10.1002\/hep.1840200104 (1994).","DOI":"10.1002\/hep.1840200104"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42879","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T19:52:45Z","timestamp":1671825165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,21]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,9]]}},"alternative-id":["BFsrep42879"],"URL":"https:\/\/doi.org\/10.1038\/srep42879","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,21]]},"assertion":[{"value":"15 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.-Y. P. has served as an advisory committee member for AbbVie, BMS, Gilead, MSD, and Roche. All other coauthors have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42879"}}